Recruiting NA Thyroid Neoplasms

New treatment option for Thyroid Neoplasms

Official title EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study

ClinicalTrials.gov ID: NCT07447089

What this study is testing

What it's testing
The main aim of the present process-outcome study is to evaluate the feasibility and the effects of an EMDR-IGTP-OTS group intervention on a sample of people with cancer, by using a process-outcome study design, with repeated measures.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 100

You may be able to join if

  • cancer diagnosis
  • PTSD (IES-R \> 32)

You likely can't join if

  • receiving specialized trauma therapy
  • receiving current psychiatric pharmacological treatment, unless the dosage has been stable for at least 2 months prior to enrollment

The study team makes the final eligibility decision.

Where it's taking place

  • Milan, Italy

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years to 100 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Milan, Italy. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.